Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Invitrogen, a division of Life Technologies, has launched Gibco OpTmizer T-cell Expansion SFM, a next-generation solution for culturing and expanding human T-cells that does not require the addition of serum to achieve optimal, cost-efficient results.
Subscribe to our email newsletter
OpTmizer SFM will enable scientists to advance their research on the central role that T-cells play in human immune response, said Invitrogen.
According to the company, OpTmizer SFM is also xeno-free, meaning that it does not contain material of non-human origin, which further enhances its safety, while decreasing variability of results from lot to lot. It is currently available in research use only grade. This product is manufactured under current good manufacturing practice regulations, and comes with an FDA drug master file to support regulatory filings.
Joydeep Goswami, vice president of Invitrogen primary and stem cell systems, Life Technologies, said: “OpTmizer is the first commercially available xeno-free T-cell media that is capable of supporting large-scale expansion of T-cells in a completely serum-free manner. This will enable an easier transition for our customers from research to clinical applications due to fewer regulatory hurdles and processing steps in T-cell expansion, and will yield greater cost savings.”